Further, the medications pathway dashboard identifies ondansetron as another potential contributor to CYP2D6 overload (but not depression directly per se) Another therapeutic option that emerges from this case is reconsidering tramadol. This evidence concerns the gene CYP2D6 and major depressive disorder.